Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Analyst Reco.
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Real-time Estimate Cboe Europe  -  08:26:04 2023-06-02 am EDT
88.16 CHF   +0.11%
08:06aNovartis drug cuts recurrence risk by 25% in early-stage breast cancer
RE
08:01aNovartis Kisqali« significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
GL
08:00aNovartis Kisqali(R) significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on NOVARTIS AG
06/01AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation
MT
05/31Analysts recommendations: Asos, Burberry, Chevron, Microsoft, N..
MS
05/22Wedbush Trims AVROBIO's PT to $2 From $4 on Heels of Announced Sale of Cystinosis Gene ..
MT
05/19NOVARTIS AG : JP Morgan sticks Neutral
MD
05/18NOVARTIS AG : UBS remains Neutral
MD
05/02NOVARTIS AG : Jefferies keeps its Buy rating
MD
04/26NOVARTIS AG : Credit Suisse maintains a Sell rating
MD
04/26NOVARTIS AG : Barclays gives a Sell rating
MD
04/26Morningstar Downgrades Novartis to Sell From Buy, $90 Price Target
MT
04/26Credit Suisse Boosts Price Target on Novartis to CHF90 From CHF80 on Higher Earnings, M..
MT
04/26NOVARTIS AG : JP Morgan reiterates its Neutral rating
MD
04/26Credit Suisse Lifts Price Target on Novartis, Maintains Underperform Recommendation
MT
04/26Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
04/26Novartis : Capable of reaching newer highs
Alphavalue
04/26NOVARTIS AG : Raised to Buy by Deutsche Bank
MD
04/25Novartis : Q1 beat, guidance upgraded, re-rating to continue
Alphavalue
04/25NOVARTIS AG : Jefferies keeps its Buy rating
MD
04/21Kepler Cheuvreux Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
04/18NOVARTIS AG : Gets a Buy rating from Jefferies
MD
04/12NOVARTIS AG : Gets a Neutral rating from JP Morgan
MD
04/11Barclays Lifts Price Target on Novartis, Maintains Underweight Recommendation
MT
04/11NOVARTIS AG : Barclays reiterates its Sell rating
MD
03/28NOVARTIS AG : UBS sticks Neutral
MD
03/28Oddo BHF Lifts Price Target on Novartis, Maintains Neutral Recommendation
MT
03/28NOVARTIS AG : Deutsche Bank Upgrades to Neutral
MD
03/27NOVARTIS AG : Jefferies gives a Buy rating
MD
03/20Novartis : Markets have high expectations of the Swiss giant
Alphavalue
03/14NOVARTIS AG : Deutsche Bank reaffirms its Sell rating
MD
02/23AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation
MT
02/17NOVARTIS AG : Deutsche Bank reaffirms its Sell rating
MD
02/13NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
MD
02/07NOVARTIS AG : Deutsche Bank gives a Sell rating
MD
02/06NOVARTIS AG : Berenberg reaffirms its Neutral rating
MD
02/03NOVARTIS AG : JP Morgan sticks Neutral
MD
02/03DA Davidson Raises Novartis AG PT to $95 From $90 After Higher-Than-Consensus Q4 2022 C..
MT
02/02NOVARTIS AG : Receives a Sell rating from Credit Suisse
MD
02/02NOVARTIS AG : Deutsche Bank reiterates its Sell rating
MD
02/02Novartis : Mixed Q4, but targeted improvements hold the key
Alphavalue
02/01NOVARTIS AG : Gets a Buy rating from Goldman Sachs
MD
02/01NOVARTIS AG : Jefferies reaffirms its Buy rating
MD
02/01NOVARTIS AG : Gets a Neutral rating from UBS
MD
01/27Novartis : Reassessing Novartis’ investment worthiness
Alphavalue
01/25NOVARTIS AG : Sell rating from Barclays
MD
01/24NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
01/09NOVARTIS AG : UBS sticks Neutral
MD
01/06NOVARTIS AG : Receives a Sell rating from Credit Suisse
MD
01/06NOVARTIS AG : Morgan Stanley downgrades from Neutral to Sell
MD
01/05NOVARTIS AG : Jefferies maintains a Buy rating
MD
01/03NOVARTIS AG : JP Morgan drops its Sell rating
MD
2022NOVARTIS AG : Sell rating from Barclays
MD
2022AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation
MT
2022AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation
MT
2022Zacks Lifts Price Target on Novartis, Maintains Neutral Recommendation
MT
2022NOVARTIS AG : UBS reiterates its Neutral rating
MD
2022NOVARTIS AG : Receives a Buy rating from Jefferies
MD
2022NOVARTIS AG : Deutsche Bank keeps a Sell rating
MD
2022NOVARTIS AG : Gets a Neutral rating from Bernstein
MD
2022NOVARTIS AG : Receives a Buy rating from Goldman Sachs
MD
2022NOVARTIS AG : Gets a Sell rating from Deutsche Bank
MD
2022NOVARTIS AG : Berenberg European Conference
FA
2022NOVARTIS AG : UBS reiterates its Neutral rating
MD
2022BNP Paribas Lowers Price Target on Novartis, Maintains Neutral Recommendation
MT
2022Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
2022Stifel Upgrades Recommendation on Novartis to Buy From Hold
MT
2022Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
2022NOVARTIS AG : Gets a Sell rating from Deutsche Bank
MD
2022Stifel Lifts Price Target on Novartis, Maintains Hold Recommendation
MT
2022Roche’s Alzheimer’s failure has sector-wide implications
Alphavalue
2022AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation
MT
2022Zacks Lifts Price Target on Novartis, Maintains Neutral Recommendation
MT
2022AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation
MT
2022NOVARTIS AG : Gets a Sell rating from Deutsche Bank
MD
2022NOVARTIS AG : Bernstein reaffirms its Neutral rating
MD
2022NOVARTIS AG : Credit Suisse maintains a Sell rating
MD
2022AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation
MT
1  2  3  4  5  6  7  8Next
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer